drugset / Trial / NCT02184988

Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines

NCT02184988

Phase 2 Completed 352 enrolled Evolus, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate the safety of multiple doses of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in treatment of moderate to severe glabellar lines in adult subjects.

Timeline

Start
2014-08
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum Toxins, Type A Unknown 20 iu Intramuscular

Indications

No indication recorded.